Business / Finance

RSS

Centric Health enters agreements to acquire Blue Water Surgical & Medical Centres, LSC

Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into agreements to acquire substantially all of the assets of Blue Water Surgical Centre Ltd., Blue Water Rejuvenation Inc., Blue Water Diagnostics Ltd. and Windsor Endoscopy Centre Ltd., along with 75% of the issued and outstanding securities of the London Scoping Centre.

19 May 2011

ShangPharma first quarter net revenues increase 25.6% to $24.8 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its first quarter ended March 31, 2011.

19 May 2011

Shamir Optical Industry first quarter revenues increase 12.8% to $45.2 million

Shamir Optical Industry Ltd., a leading provider of innovative products and technology to the ophthalmic lens market, today announced unaudited financial results for the first quarter ended March 31, 2011.

19 May 2011

USANA to expand business operations into Thailand in fourth quarter 2011

USANA Health Sciences, Inc. today announced plans to expand into Thailand in the fourth quarter of 2011. This will be USANA's 16th market in which independent distributors sell USANA's high quality, science-based products.

19 May 2011

Takeda reaches agreement to acquire Nycomed

Takeda Pharmaceutical Company Limited and Nycomed A/S jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis.

19 May 2011

Metabolix initiates public offering of common stock

Metabolix, Inc., a bioscience company focused on developing sustainable solutions for plastics, chemicals and energy, today announced that it has commenced a public offering of shares of its common stock pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission.

19 May 2011

OctreoPharm Sciences granted SME status by the EMA

OctreoPharm Sciences GmbH, a medicine developer and specialist for radioactive labeled contrast agents in nuclear medicine has been granted SME status as small-sized enterprise in research and development by the European Medicine Agency EMA.

18 May 2011

Momentive Performance Materials collaborates with SSF to develop combination products

Momentive Performance Materials Inc. today announced a collaboration initiative with Specialty Silicone Fabricators (SSF) to develop combination products for medical devices manufacturers.

18 May 2011

LabCorp announces extension of cash tender offer for outstanding shares of Orchid Cellmark

Laboratory Corporation of America® Holdings today announced that LabCorp is extending until 6:00 p.m., New York City time, on June 1, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common stock of Orchid Cellmark Inc.

18 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

Cameron Health announces completion of $107 million equity financing round

Cameron Health, Inc., developer of the world's only completely subcutaneous implantable defibrillator, announced today that it has completed a $107 million equity financing round led by Alloy Ventures and Delphi Ventures.

18 May 2011

Thermo Fisher Scientific acquires Sterilin

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has acquired Sterilin, Ltd., a leading provider of single-use plastic products serving the microbiology, life sciences and clinical markets.

From Thermo Fisher Scientific Inc. 18 May 2011

Abiomed fiscal fourth quarter revenue increases 24% to $28.5 million

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2011 revenue of $28.5 million, up 24% compared to revenue of $23.0 million in the same period of fiscal 2010.

18 May 2011

Centene prices public offering of $250 million senior notes

Centene Corporationtoday announced that on May 17, 2011 it priced $250 million aggregate principal amount of its senior notes in a public offering made pursuant to a registration statement and a related preliminary prospectus supplement filed by Centene with the Securities and Exchange Commission.

18 May 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

Concord Medical first quarter total net revenues increase 14.7% to $13.3 million

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the first quarter ended March 31, 2011.

18 May 2011

Clinipace Worldwide announces acquisition of PFC

Clinipace Worldwide, a global digital clinical research organization, and Swiss-based PFC Pharma Focus today jointly announced a definitive merger agreement under which Clinipace Worldwide has acquired all outstanding shares of privately-held PFC and its subsidiaries.

18 May 2011

Ampio's common stock to be listed on NASDAQ Capital Market

Ampio Pharmaceuticals, Inc., a clinical stage developer of new uses for previously approved drugs and new molecular entities, announces that its common stock has been approved for listing on the NASDAQ Capital Market.

18 May 2011

Thermo Fisher Scientific acquires Dionex

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has successfully completed its acquisition of Dionex Corporation through a short-form merger.

From Thermo Fisher Scientific Inc. 18 May 2011

Excaliber subsidiary merges with VistaGen

Excaliber Enterprises, Ltd. announced today that its wholly-owned subsidiary has merged with VistaGen Therapeutics, Inc., a private biotechnology company focused on stem cell-based drug rescue and drug development. As a result of the Merger, VistaGen is a wholly-owned subsidiary of Excaliber.

17 May 2011